Novavax Announces Presentation of Phase 3 Data from RSV Maternal Immunization Program at 37th Annual Meeting of the European Society for Pediatric Infectious Diseases

GAITHERSBURG, Md., May 01, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced that Flor M. Muñoz, M.D., M.Sc., Associate Professor of Pediatrics Molecular Virology and Microbiology at Baylor College of Medicine and Medical Director, Transplant Infectious Diseases, Texas Children’s Hospital, will present data from the company’s global Phase 3 clinical trial of ResVax™ at the 37th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID) in Ljubljana, Slovenia, being held May 6-11, 2019. ResVax is Novavax’ respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine.

Details are as follows:

Abstract title:			Phase 3 PREPARE study: efficacy and safety of an RSV vaccine administered to pregnant women
Session title:			PIDS/ESPID Joint Plenary Symposium – The future of vaccines (is now)
Session code and track:			ST01; Science track
Location:			Kocka Hall
Date:			Tuesday, May 7
Time:			10:30 a.m. ET

The abstract for the presentation can be found here. In addition, the presentation will be live streamed. For more information, please visit the ESPID meeting’s website.

About ResVax™ and the Prepare Trial

ResVax is an RSV fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant. It is being developed to protect infants from RSV disease via maternal immunization, which may offer the best method of protection from RSV disease in infants through the first months of life. In February 2019, Novavax announced top-line data from Prepare™, a global Phase 3 clinical trial in 4,636 pregnant women, at least 3,000 of whom have received the vaccine, and their infants. Prepare is supported by an $89.1 million grant from the Bill & Melinda Gates Foundation (BMGF).

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that drives improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Its two priority programs are ResVax™, its RSV vaccine for infants via maternal immunization, and NanoFlu™, its quadrivalent influenza nanoparticle vaccine. Novavax’ proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:      

Investors
Novavax, Inc.
Erika Trahan
ir@novavax.com
240-268-2000

Westwicke
John Woolford
john.woolford@westwicke.com
443-213-0506

Media
Sam Brown
Andrea Cohen
andreacohen@sambrown.com
917-209-7163